- Home
- DINO vs JAZZ Comparison
DINO vs JAZZ Comparison
Compare DINO & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DINO
- JAZZ
- Stock Information
- Founded
- DINO 1947
- JAZZ 2003
- Country
- DINO United States
- JAZZ Ireland
- Employees
- DINO N/A
- JAZZ N/A
- Industry
- DINO Oil & Gas Production
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- DINO Energy
- JAZZ Health Care
- Exchange
- DINO Nasdaq
- JAZZ Nasdaq
- Market Cap
- DINO 6.6B
- JAZZ 6.1B
- IPO Year
- DINO N/A
- JAZZ 2007
- Fundamental
- Price
- DINO $29.03
- JAZZ $102.78
- Analyst Decision
- DINO Buy
- JAZZ Strong Buy
- Analyst Count
- DINO 10
- JAZZ 13
- Target Price
- DINO $46.25
- JAZZ $187.15
- AVG Volume (30 Days)
- DINO 3.9M
- JAZZ 1.6M
- Earning Date
- DINO 05-01-2025
- JAZZ 04-30-2025
- Dividend Yield
- DINO 7.04%
- JAZZ N/A
- EPS Growth
- DINO N/A
- JAZZ 41.75
- EPS
- DINO 0.91
- JAZZ 8.65
- Revenue
- DINO $28,580,000,000.00
- JAZZ $4,068,950,000.00
- Revenue This Year
- DINO $0.37
- JAZZ $7.60
- Revenue Next Year
- DINO $0.09
- JAZZ $3.43
- P/E Ratio
- DINO $31.90
- JAZZ $11.88
- Revenue Growth
- DINO N/A
- JAZZ 6.12
- 52 Week Low
- DINO $24.66
- JAZZ $95.49
- 52 Week High
- DINO $58.73
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- DINO 44.27
- JAZZ 31.87
- Support Level
- DINO $27.33
- JAZZ $100.42
- Resistance Level
- DINO $28.57
- JAZZ $104.12
- Average True Range (ATR)
- DINO 1.91
- JAZZ 6.41
- MACD
- DINO -0.03
- JAZZ -1.27
- Stochastic Oscillator
- DINO 48.66
- JAZZ 22.51
About DINO HF Sinclair Corporation
HF Sinclair is an integrated petroleum refiner that owns and operates seven refineries serving the Rockies, midcontinent, Southwest, and Pacific Northwest, with a total crude oil throughput capacity of 678,000 barrels per day. It can produce 380 million gallons of renewable diesel annually. It holds a marketing business with over 300 distributors and 1,500 wholesale branded sites across 30 states. It also owns and operates 4,400 miles of petroleum product pipelines and terminals principally in the southwestern United States.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.